Table 2.
Demographic and tele-harm reduction component comparisons between those retained and not retained in buprenorphine treatment at three months.
| Characteristic | Retained at three months (n = 64) | Not retained at three months (n = 45) | p Value |
|---|---|---|---|
| Age (n,%) | .91 | ||
| < =29 years old | 12 (60.0) | 8 (40.0) | |
| 30–39 years old | 22 (56.4) | 17 (43.6) | |
| 40–59 years old | 27 (58.7) | 19 (41.3) | |
| > =60 | 3 (75.0) | 1 (25.0) | |
| Biological sex (n,%) | .32 | ||
| Male | 50 (61.0) | 32 (39.0) | |
| Female | 13 (50.0) | 13 (50.0) | |
| Race/ethnicity (n,%) | .61 | ||
| Non-Hispanic White | 34 (63.0) | 20 (37.0) | |
| Non-Hispanic Black | 8 (50.0) | 8 (50.0) | |
| Hispanic | 22 (56.4) | 17 (43.6) | |
| Insurance status at enrolment (n,%) | .03 | ||
| Insured | 7 (63.6) | 4 (36.4) | |
| Uninsured | 42 (51.9) | 39 (48.2) | |
| Underinsured | 14 (87.5) | 2 (12.5) | |
| Housing status at enrolment (n,%) | .13 | ||
| Stably housed | 20 (54.1) | 17 (46.0) | |
| Unstably housed (in shelter) | 28 (71.8) | 11 (28.2) | |
| Rough sleeping (street) | 16 (50.0) | 16 (50.0) | |
| IDEA SSP participant (n,%) | 40 (61.5) | 25 (38.5) | .47 |
| Stimulant use at baseline | 27 (46.6) | 31 (53.5) | <.01 |
| Saw provider via Telehealth in first three months (n,%) | 54 (75.0) | 18 (25.0) | <.01 |
| Escalated buprenorphine dose post baseline (n,%) | 26 (86.7) | 4 (13.8) | <.01 |